Business
VVT Med Announces Closing of Shares for Debt Transaction
VVT Med Inc. ("VVT Med" or the "Company"), a developer of innovative minimally invasive solutions for the treatment of venous disease, is pleased to announce that further to its news release dated November 11, 2025, the Company has closed its previously announced debt settlement (the "Debt Settlement") with various vendors of the Company (the "Creditors").
About this update from Vvt Med Inc.
[{"type":"text","content":"VANCOUVER, BC, April 15, 2026 /CNW/ - VVT Med Inc. ("VVT Med" or the "Company"), a developer of innovative minimally invasive solutions for the treatment of venous disease, is pleased to announce that further to its news release dated November 11, 2025, the Company has closed its previously announced debt settlement (the "Debt Settlement") with various vendors of the Company (the "Creditors").","length":436,"tagName":"p"},{"type":"text","content":"Pursuant to the Debt Settlement, the Company entered into debt settlement agreements with the Creditors to settle an aggregate of $373,057.20 of debt owed by the Company to the Creditors by issuing an aggregate of 1,203,410 common shares of the Company at a deemed price of $0.31 per share.","length":290,"tagName":"p"},{"type":"text","content":"The completion of the Debt Settlement remains subject to final acceptance by the TSX Venture Exchange (the "TSXV"). All securities issued pursuant to the Debt Settlement have been issued pursuant to a prospectus exemption and are subject to a four month and one day hold period that expires on August 16, 2026.","length":320,"tagName":"p"},{"type":"text","content":"About VVT Med Inc. (VVTM)","length":25,"tagName":"p"},{"type":"text","content":"VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient, and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration.","length":691,"tagName":"p"},{"type":"text","content":"About I3 Capital","length":16,"tagName":"p"},{"type":"text","content":"I3, a cross-border capital advisory services firm with offices in Toronto, Miami and Tel Aviv. I3 offers investor relations, corporate finance, M&A and equity research services for innovative, high-growth companies that are listed or seeking to list on N...